文献速递心脑血管急症

依维莫司洗脱生物可吸收支架与依维莫司洗脱金属支架治疗冠状动脉狭窄的比较(ABSORB II):3年随机对照单盲多中心临床试验

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
PubMed 文献 · Lancet · 2016-10-30
一句话结论ABSORB II 3年结果:Absorb生物可吸收支架未达到血管舒缩反应优效与晚期管腔丢失非劣效的共同主要终点,且器械导向复合终点更高(10% vs 5%,HR 2.17)。

ABSORB II 为前瞻性、随机、阳性对照、单盲、平行两组、多中心临床试验,纳入18-85岁有心肌缺血证据且不同心外膜血管存在一或两处新发原生病变的患者,按2:1随机接受依维莫司洗脱生物可吸收支架(Absorb)或依维莫司洗脱金属支架(Xience)治疗。3年随访时,血管舒缩反应两组无统计学差异(Absorb 0.047 mm vs Xience 0.056 mm,优效性 p=0.49),晚期管腔丢失 Absorb 组大于 Xience 组(0.37 mm vs 0.25 mm,非劣效性 p=0.78),血管内超声所测最小管腔面积亦证实该差异(4.32 mm² vs 5.38 mm²,p<0.0001)。器械导向复合终点 Absorb 组显著高于 Xience 组(10% vs 5%,HR 2.17,95%CI 1.01-4.70,log-rank p=0.0425),主要由靶血管心肌梗死驱动(6% vs 1%,p=0.0108)。患者导向复合终点、西雅图心绞痛问卷评分及运动试验两组无统计学差异。

要点

  • 3年血管舒缩反应 Absorb 组 0.047 mm(SD 0.109)vs Xience 组 0.056 mm(SD 0.117),优效性检验 p=0.49,未达统计学差异。
  • 3年晚期管腔丢失 Absorb 组 0.37 mm(SD 0.45)vs Xience 组 0.25 mm(SD 0.25),非劣效性检验 p=0.78,Absorb 组更大。
  • 血管内超声最小管腔面积 Absorb 组 4.32 mm²(SD 1.48)vs Xience 组 5.38 mm²(SD 1.51),p<0.0001。
  • 器械导向复合终点 Absorb 组 10% vs Xience 组 5%(HR 2.17,95%CI 1.01-4.70;log-rank p=0.0425),主要由靶血管心肌梗死驱动(6% vs 1%,p=0.0108)。
  • 患者导向复合终点、西雅图心绞痛问卷评分及运动试验两组无统计学差异。

适用人群与场景

  • 年龄18-85岁、有心肌缺血证据、不同心外膜血管存在一或两处新发原生病变的患者。

研究设计与关键结果

  • ABSORB II 为前瞻性、随机、阳性对照、单盲、平行两组、多中心临床试验,2011年11月28日至2013年6月4日共纳入501例患者,按2:1随机分为 Absorb 组(335例,364处病变)与 Xience 组(166例,182处病变),随机化按糖尿病状态和计划靶病变数量分层。
  • 3年主要终点血管舒缩反应(冠状动脉内硝酸酯后血管造影评估)Absorb 组 0.047 mm(SD 0.109)vs Xience 组 0.056 mm(SD 0.117),优效性检验 p=0.49,未达统计学差异。
  • 共同主要终点晚期管腔丢失 Absorb 组 0.37 mm(SD 0.45)vs Xience 组 0.25 mm(SD 0.25),非劣效性检验 p=0.78(非劣效界值0.14 mm),Absorb 组晚期管腔丢失更大。
  • 血管内超声最小管腔面积 Absorb 组 4.32 mm²(SD 1.48)vs Xience 组 5.38 mm²(SD 1.51),p<0.0001。
  • 器械导向复合终点 Absorb 组 10% vs Xience 组 5%(HR 2.17,95%CI 1.01-4.70;log-rank p=0.0425),主要由靶血管心肌梗死驱动(6% vs 1%,p=0.0108),其中围手术期心肌梗死 Absorb 组 4% vs Xience 组 1%(p=0.16)。
  • 患者导向复合终点、西雅图心绞痛问卷评分及运动试验在两组间无统计学差异。

证据类型、等级与局限

  • 证据类型:前瞻性、随机、阳性对照、单盲、平行两组、多中心临床试验。
  • 试验未达到血管舒缩反应优效与晚期管腔丢失非劣效的共同主要终点。
  • 作者指出未来研究应探讨精确血管内影像在器械尺寸选择和优化支架植入中的临床影响,以及生物可吸收支架植入后延长双联抗血小板治疗的获益与必要性。

对床旁实践的改变

  • 作者认为未来研究应探讨精确血管内影像在器械尺寸选择和优化支架植入中的临床影响。
  • 作者提出生物可吸收支架植入后延长双联抗血小板治疗的获益与必要性可成为未来临床研究的主题。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: No medium-term data are available on the random comparison between everolimus-eluting bioresorbable vascular scaffolds and everolimus-eluting metallic stents. The study aims to demonstrate two mechanistic properties of the bioresorbable scaffold: increase in luminal dimensions as a result of recovered vasomotion of the scaffolded vessel.

METHODS: The ABSORB II trial is a prospective, randomised, active-controlled, single-blind, parallel two-group, multicentre clinical trial. We enrolled eligible patients aged 18-85 years with evidence of myocardial ischaemia and one or two de-novo native lesions in different epicardial vessels. We randomly assigned patients (2:1) to receive treatment with an everolimus-eluting bioresorbable scaffold (Absorb; Abbott Vascular, Santa Clara, CA, USA) or treatment with an everolimus-eluting metallic stent (Xience; Abbott Vascular, Santa Clara, CA, USA). Randomisation was stratified by diabetes status and number of planned target lesions. At 3 year follow-up, the primary endpoint was superiority of the Absorb bioresorbable scaffold versus the Xience metallic stent in angiographic vasomotor reactivity after administration of intracoronary nitrate. The co-primary endpoint is the non-inferiority of angiographic late luminal loss. For the endpoint of vasomotion, the comparison was tested using a two-sided t test. For the endpoint of late luminal loss, non-inferiority was tested using a one-sided asymptotic test, against a non-inferiority margin of 0·14 mm. The trial is registered at ClinicalTrials.gov, number NCT01425281.

FINDINGS: Between Nov 28, 2011, and June 4, 2013, we enrolled 501 patients and randomly assigned them to the Absorb group (335 patients, 364 lesions) or the Xience group (166 patients, 182 lesions). The vasomotor reactivity at 3 years was not statistically different (Absorb group 0·047 mm [SD 0·109] vs Xience group 0·056 mm [0·117]; psuperiority=0·49), whereas the late luminal loss was larger in the Absorb group than in the Xience group (0·37 mm [0·45] vs 0·25 mm [0·25]; pnon-inferiority=0·78). This difference in luminal dimension was confirmed by intravascular ultrasound assessment of the minimum lumen area (4·32 mm2 [SD 1·48] vs 5·38 mm2 [1·51]; p<0·0001). The secondary endpoints of patient-oriented composite endpoint, Seattle Angina Questionnaire score, and exercise testing were not statistically different in both groups. However, a device-oriented composite endpoint was significantly different between the Absorb group and the Xience group (10% vs 5%, hazard ratio 2·17 [95% CI 1·01-4·70]; log-rank test p=0·0425), mainly driven by target vessel myocardial infarction (6% vs 1%; p=0·0108), including peri-procedural myocardial infarction (4% vs 1%; p=0·16).

INTERPRETATION: The trial did not meet its co-primary endpoints of superior vasomotor reactivity and non-inferior late luminal loss for the Absorb bioresorbable scaffold with respect to the metallic stent, which was found to have significantly lower late luminal loss than the Absorb scaffold. A higher rate of device-oriented composite endpoint due to target vessel myocardial infarction, including peri-procedural myocardial infarction, was observed in the Absorb group. The patient-oriented composite endpoint, anginal status, and exercise testing, were not statistically different between both devices at 3 years. Future studies should investigate the clinical impact of accurate intravascular imaging in sizing the device and in optimising the scaffold implantation. The benefit and need for prolonged dual antiplatelet therapy after bioresorbable scaffold implantation could also become a topic for future clinical research.

FUNDING: Abbott Vascular.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016. PMID: 27806897. doi:10.1016/S0140-6736(16)32050-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。